Bank of America
PCSA icon

Bank of America’s Processa Pharmaceuticals PCSA Stock Holding History

Bank of America’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18
Closed -$52 – 6571
2025
Q4 		$52 Buy
18
+3
+20% +$21 ﹤0.01% 6953
2025
Q3 		$72 Buy
15
+11
+275% +$58 ﹤0.01% 7928
2025
Q2 		$22 Buy
4
+3
+300% +$20 ﹤0.01% 8234
2025
Q1 		$14 Hold
1
– – ﹤0.01% 8183
2024
Q4 		$22 Hold
1
– – ﹤0.01% 8010
2024
Q3 		$33 Hold
1
– – ﹤0.01% 7890
2024
Q2 		$47 Sell
1
-5
-83% -$246 ﹤0.01% 7854
2024
Q1 		$378 Buy
+6
New +$475 ﹤0.01% 7299
2023
Q1 		– Hold
0
– -$15 – 8154
2022
Q4 		– Hold
0
– – – 8033
2022
Q1 		– Hold
0
– – – 8631
2021
Q4 		– Hold
0
– – – 8532
2021
Q2 		– Hold
0
– – – 7996
2021
Q1 		– Hold
0
– – – 7687

Other funds holding PCSA

CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of America's PCSA Position: Q1 2026 in Review

Bank of America sold out of Processa Pharmaceuticals (PCSA) in Q1 2026, closing a stake of 18 shares — an estimated $52 sold.

Bank of America first reported a position in PCSA in Q1 2024 and held it in 8 quarters. The position peaked at $378 in Q1 2024. 10 funds tracked by Wall St. Rank hold PCSA as of Q1 2026.

  • Bank of America reported no remaining Processa Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 18 Processa Pharmaceuticals shares in Q1 2026, an estimated $52.
  • Bank of America first reported a position in Processa Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Bank of America's Processa Pharmaceuticals position peaked at $378 in Q1 2024.
  • 10 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.